RESUMO
OBJECTIVE: The aim of this study was to evaluate baseline differences by HIV status and the impact of pomalidomide on lymphocyte counts and T-cell subsets in patients with Kaposi sarcoma. DESIGN: We prospectively evaluated CD4 + and CD8 + T-cell phenotypes in 19 participants with Kaposi sarcoma enrolled on a phase 1/2 study of pomalidomide (NCT01495598), seven without HIV and 12 with HIV on antiretroviral therapy. METHODS: Trial participants received pomalidomide 5âmg orally for 21âdays of 28-day cycles for up to 1âyear. Flow cytometry was performed on peripheral blood mononuclear cells at baseline, after three cycles, and at end-of-treatment. Lymphocyte count and T-cell subset comparisons were evaluated by Wilcoxon signed-rank and Mann--Whitney tests. RESULTS: At baseline, HIV + participants had lower CD4 + cell counts (median 416 vs. 742 CD4 + T cells/µl, P â=â0.006), and a decreased proportion of CD57 + (senescent) CD8 + T cells ( P â=â0.007) compared with HIV - participants. After three cycles, pomalidomide led to an increased proportion of CD45RO + CD27 + (central memory) CD4 + ( P â=â0.002) and CD8 + ( P â=â0.002) T cells, a decrease in CD45RO - CD27 - (effector) CD4 + cells ( P â=â0.0002), and expansion of CD38 + /HLADR + (activated) CD4 + ( P â=â0.002) and CD8 + ( P â≤â0.0001) T cells. Increased numbers of activated CD8 + T cells persisted at end-of-treatment ( P â=â0.002). After three cycles and at end-of-treatment, there was reduction in the proportion of CD57 + (senescent) CD4 + ( P â=â0.001, 0.0006), and CD8 + ( P â=ââ<â0.0001, 0.0004) T cells. CONCLUSION: Administration of pomalidomide decreased T-cell senescence and increased T-cell activation in patients with Kaposi sarcoma, suggesting pomalidomide activity in Kaposi sarcoma stems in part from its immunomodulatory effects.